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A growing body of evidence suggests the existence of biochemical and functional 
interactions between the endocannabinoid and orexin systems. Cannabinoid and orexin 
receptors have been shown to form heterodimers in agreement with the overlapping 
distribution of both receptors in several brain areas, and the activation of common 
intracellular signaling pathways, such as the MAP kinase cascade. The activation of 
orexin receptors induces the synthesis of the endocannabinoid 2-arachidonoyl glycerol 
suggesting that the endocannabinoid system participates in some physiological functions 
of orexins. Indeed, functional interactions between these two systems have been 
demonstrated in several behavioral responses including nociception, reward and food 
intake. The present review is focused on the latest developments in cannabinoid-orexin 
cross-modulation and the implications of this interesting interaction.  
 




1. The endocannabinoid and orexin systems 
The endocannabinoid system (ECS) consists of two main endogenous ligands: 
anandamide (AEA) and 2-arachidonoylglycerol (2-AG) called endocannabinoids, the 
synthetizing enzymes: diacylglycerol lipase-α (DAGL) and N-
acylphosphatidylethanolamine-phospholipase D (NAPE-PLD), the degradation enzymes: 
fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), and two major 
G protein-coupled receptors (GPCR): the cannabinoid type 1 (CB1R) and type 2 (CB2R) 
receptors. Other putative cannabinoid receptors have been described including the 
vanilloid type 1 receptor (TRPV1) [1], and the G protein-coupled receptor 55 (GPR55) 
[2]. Endocannabinoids are lipid signaling molecules that display distinct pharmacological 
profiles, as well as regional diversity [3]. Different to most neurotransmitters, they are 
not stored in presynaptic vesicles, but are synthetized and released on demand in the 
postsynaptic terminals in response to elevations of intracellular Ca2+ [4]. These 
compounds act as retrograde synaptic messengers travelling across synapses, where they 
bind to presynaptic cannabinoid receptors located in both neurons [5] and glia [6] to 
modulate neurotransmitter release. CB1R are the most abundant GPCR in the central 
nervous system (CNS) [7] and are widely distributed in the brain in areas such as the 
cortex, hippocampal formation, basal ganglia, and cerebellum [8]. In all these structures, 
CB1R are localized presynaptically on serotonergic, noradrenergic, dopaminergic, 
GABAergic, and glutamatergic nerve terminals [9–11]. However, there is also data 
demonstrating a postsynaptic localization for CB1R [12,13] in cortical dendrites where 
they can modulate self-inhibition processes [14,15], and in dendrites of a subset of 
hippocampal pyramidal neurons that upon activation recruit c-Jun-N-terminal kinases and 
nitric oxide [16]. In addition, CB1R are present intracellularly in mitochondria, at both 
presynaptic terminals and at somatodendritic compartments of glutamatergic and 
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GABAergic hippocampal neurons [17]. Both cannabinoid CB1R and CB2R are mainly 
coupled to Gi/o resulting in the inhibition of the adenylate cyclase/cAMP cascade and 
voltage-gated Ca2+ channels, as well as the stimulation of inwardly rectifying K+ 
currents, and of mitogen-activated protein kinase (MAPK) activity [18]. Interestingly, a 
growing amount of evidence shows that CB1R can couple with different subunits of the 
classic inhibitory Gi/o proteins, but also with Gαz, Gαq/11, and Gα12/13 [19,20], and 
that under specific circumstances, CB1R can shift toward activation of Gs and 
potentiation of neurotransmission [21,22]. In addition, activation of CB1R in astrocytes 
increases intracellular calcium probably mediated by Gq proteins [23], and in the 
cardiovascular system, CB1R can bind to Gs or Gq/11 to modulate vasoconstriction and 
hypertension [24]. The ECS is involved in a wide variety of brain processes including 
brain plasticity, learning and memory, nociception, inflammation, appetite regulation, 
metabolism, energy balance, sleep–wake cycle, regulation of stress, emotions, reward and 
addiction [25–27]. Fundamentally, this neuroregulatory system is highly complex and a 
great amount of research is still being carried out to understand more about the intricate 
ways in which the ECS functions in normal and pathological states.  
The orexin/hypocretin (OX) system is composed of two endogenous ligands: OX-A/ 
hypocretin-1 and OX-B/ hypocretin-2, and two GPCRs: the OX-1/ hypocretin-1 (OX1R) 
and the OX-2/ hypocretin-2 (OX2R) receptors.  OX-A and OX-B are neuropeptides 
produced from a common precursor peptide by a cascade of enzymatic reactions [28,29]. 
OX-A is a 33 amino acid peptide activating both OX1R and OX2R with similar potencies, 
whereas OX-B is a 28 amino acid peptide that is modestly selective for the OX2R [28]. 
OX-expressing cell bodies are specifically localized in the lateral and perifornical areas 
of the hypothalamus, but their projections are widely distributed throughout the CNS [28–
31]. The OX receptors are abundantly expressed in the cerebral cortex, basal ganglia, 
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ventral tegmental area (VTA), nucleus accumbens, hippocampus, hypothalamic and 
thalamic nuclei, dorsal and medial raphe, locus coeruleus (LC), preoptic area, 
periaqueductal gray (PAG) and reticular formation [32]. OX1R activation triggers 
signaling through Gq/11 proteins resulting in activation of phospholipase C with 
subsequent initiation of the phosphatidylinositol cascade. However, in Chinese hamster 
ovary (CHO) cells expressing OX1R, other types of signaling have been described such 
as coupling to phospholipase A2 and DAGL, with the subsequent production of 2-AG 
[33], or Gi-protein coupling with inhibition of AC [34]. In addition, in primary neuronal 
cell cultures from rat cerebral cortex [35] and in primary cultures of rat astrocytes [36], 
OX1R stimulate cAMP production. OX2R have also been shown to couple with multiple 
G proteins including both Gq/11 and inhibitory Gi proteins [37]. Stimulation of both 
receptors activates the MAP kinase pathway leading to ERK1/2 and p38 kinase 
phosphorylation [38,39]. The OX system is involved in the control of numerous 
physiological functions and behaviors including attention, alertness, locomotion, 
regulation of sleep, reward and motivational processes, food intake, energy balance and 
metabolism [40]. OXs also have antinociceptive effects at spinal and supraspinal levels 
in several pain models [41], and are involved in stress-induced analgesia [42]. 
The ECS and OX system have common anatomical distributions in the CNS and thus 
share physiological functions [8,32,43].  OX1R, OX2R and CB1R are widely expressed 
in the hypothalamus where they regulate energy homeostasis and central neuroendocrine 
and autonomic functions [40,44]. In the mesocorticolimbic system, the septal nuclei and 
the amygdaloid nuclei, both OX receptors and CB1R co-exist and regulate natural reward 
and addiction processes [45–47]. Moreover, these receptors are located in brain stem 
areas such as the raphe nuclei, the LC, the reticular formation and the PAG, where they 
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are involved in the regulation of anxiety-like responses, sleep/wake cycle and nociception 
[48–50]. 
This review is not set out to be an exhaustive account of the functions of the ECS and OX 
system, but rather an update of the bidirectional interactions between these systems that 
have been reported in the last years, specifically in the areas of appetite regulation and 
energy balance, nociception and reward processes. 
 
2. Biochemical interactions between orexins and cannabinoids 
A growing body of biochemical and functional evidence suggests that GPCRs, 
historically considered monomers, form and function as homo- and heterodimers, or even 
higher-ordered oligomers. These dimers/oligomers often display unique ligand binding, 
distinct phenotypic trafficking, and specific signaling properties in comparison with their 
individual monomers [51,52]. Congruent with an overlapping distribution of CB1R and 
OX1R in certain brain areas, the first evidence of functional cross-talk between these 
receptors was demonstrated by co-expression of CB1R and OX1R in CHO cells [53]. 
Thus, a major CB1R-dependent enhancement of OX-A’s potency to activate the MAPK 
pathway was shown, and this effect required functional CB1R since the specific CB1R 
antagonist rimonabant blocked this response. Moreover, by electron microscopy 
experiments, the authors concluded that CB1R and OX1R were close enough to form 
hetero-oligomers [53]. The possible existence of CB1R-OX1R heteromerization was 
further assessed by co-expressing both receptors in HEK293 cells [54]. Treatment with 
rimonabant resulted in decreased potency of OX-A to activate the MAPK ERK1/2 only 
in cells co-expressing the two receptors. The OX1R antagonist SB-674042 also reduced 
the potency of a CB1R receptor agonist to phosphorylate ERK1/2 only when the two 
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receptors were co-expressed [54]. Moreover, single cell fluorescence resonance energy 
transfer (FRET) imaging indicated that both CB1R and OX1R were present as 
heterodimers/oligomers in intracellular vesicles [54]. More recently, the same group 
provided further evidence of such heteromerization based on covalent labeling of 
extracellular domains of CB1R and OX1R with “SNAP” and “CLIP” tags. These are 
polypeptides which can be labeled covalently with a variety of reagents such as cell-
impermeant fluorophores, allowing reliable monitoring of these heteromers at the cell 
surface [55]. Interestingly, a higher potency of OX-A to regulate the CB1R-OXR1 
heteromer compared with the OX1R-OX1R homomer was found in this study, suggesting 
a functional interplay between these two systems [55]. The formation of CB1R-OX1R 
heteromeric complexes has been recently demonstrated in embryonic mouse 
hypothalamic neurons [56]. These heteromers were found to affect intracellular calcium 
levels, 2-AG biosynthesis and ERK phosphorylation [56]. In addition, by using a 
bioluminescence energy transfer (BRET) assay, both OX1R and OX2R subtypes were 
shown to be capable of forming constitutive homo- and heteromeric complexes with one-
another and with CB1R  [57]. However, although all these data provide unequivocal 
identification of CB1R-OX1R heteromerization, whether these complexes are functional 
under physiological conditions, and whether they are dynamically regulated remains to 
be elucidated [58]. The development of bivalent ligands, which preferentially interact 
with the receptor heterodimers, will represent a possible approach of determining their 
physiological significance [59]. 
Apart from heteromerization, some studies suggest that the most important part of the 
interaction between CB1R and OX1R results from 2-AG production in response to OX 
stimulation [60]. Release of 2-AG following the administration of OX-A has been 
demonstrated in CHO cells [33]. In these cells, the activation of PLC was shown to be 
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responsible for DAG production, which in turn is used by DAGL as a substrate for 2-AG 
formation [33]. Therefore, it is possible that the activation of CB1R by 2-AG could 
contribute to increase the potency of OX signaling observed in CHO cells. Moreover, as 
it will be described later in this review, this OX-induced 2-AG release has been 
demonstrated to be of great relevance in several studies. Thus, 2-AG modulates the effects 
of OXs on nociception, addiction and food intake. 
 
3. Involvement of endocannabinoids in the effects of orexins on food intake and 
energy balance 
The OX system is a key modulator of both food intake and energy expenditure. Under 
physiological conditions, hormonal control of food intake is mainly mediated by the 
action of leptin and ghrelin in the hypothalamus, where they exert opposing effects on the 
activity of anorexigenc pro-opiomelanocortin (POMC)/cocaine-amphetamine-related 
transcripts (CART), and orexigenic agouti-related peptide (AgRP)/neuropeptide Y (NPY) 
neurons in the arcuate nucleus. Leptin, produced by adipocytes, indirectly controls the 
activity of OX neurons via long form leptin receptors (LepRb) in neurotensin-expressing 
cells in the lateral hypothalamus (LH) [61,62], and through the action of neuropeptides 
released from the POMC or AgRP/NPY neurons [63,64]. On the other hand, ghrelin 
released during fasting directly activates OX neurons by binding to ghrelin receptors 
(GHSR) located in these neurons [65–67]. Correspondingly, OX stimulates orexigenic 
NPY-containing neurons and decreases the activity of anorexigenic POMC-containing 
neurons, via OX1R [68,69]. Thus, the control of feeding by OX involves local 
bidirectional interactions in the hypothalamus between OX neurons and NPY and POMC 
cells [70–73], their modulation by peripheral hormones, and their output connections to 
limbic, locomotor, autonomic and neuroendocrine systems [28,29,74]. 
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Furthermore, the control of the pathways involved in homeostatic food intake is 
preponderantly modulated by the ECS. Thus, the levels of 2-AG increase in the 
hypothalamus in normal animals during fasting, decrease during refeeding, and return to 
normal when rats are satiated [75], while in rodent models of obesity, elevated levels of 
endocannabinoids within hypothalamic nuclei have been observed [76,77]. In addition, a 
wide distribution of CB1R has been demonstrated in the hypothalamus, with a 
presynaptic localization on GABAergic terminals innervating NPY/AgRP and melanin-
concentrating hormone (MCH) neurons and on glutamatergic projections to OX neurons 
[78], and positioned post-synaptically on POMC/CART [69] and corticotrophin-releasing 
hormone [25] neurons. Under physiological conditions, the orexigenic action of 
cannabinoids has been attributed mainly to their excitatory effect on MCH cells mediated 
by inhibition of inhibitory GABAergic input to these neurons. In contrast, cannabinoids 
reduce the activity of OX cells due to the presynaptic attenuation of glutamate release, 
leading to a decrease in arousal [78]. In addition, it has been shown that the peripheral 
administration of sub-threshold doses of the CB1R antagonist rimonabant blocks the 
orexigenic effect of OX-A administered by intracerebroventricular route [79]. The ECS 
may influence food intake by regulating the expression and/or action of OXs. Thus, 
intracerebroventricular injection of the CB1R inverse agonist AM251 produced a 
significant decrease in the number of neurons expressing OX-A in the hypothalamus [80].  
In conditions where hormone levels are dysregulated, such as in obesity, OX neurons may 
contribute to hyperphagia and obesity [81]. Indeed, in leptin-knockout (ob/ob), and in 
diet-induced obese mice the balance between GABA/Glutamatergic innervation to OX 
cells is shifted to predominantly inhibitory CB1R-expressing inputs. An overexpression 
of the biosynthetic enzyme for the endocannabinoid 2-AG, DAGL, was also observed in 
these animals. These changes were reversed by leptin administration. Notably, these 
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alterations lead to a retrograde inhibition of GABAergic terminals by 2-AG, increased 
neuronal activity of OX cells, and enhanced signaling activity in projection areas 
mediating reward, motivation and food intake, such as the VTA, nucleus accumbens and 
arcuate nucleus [81]. Subsequent electrophysiological studies in slices from the LH of 
ob/ob mice confirmed that the upregulation of 2-AG by OX neurons leads mainly to a 
depression of inhibition, and consequently the excitatory drive on OX neurons becomes 
functionally predominant [82]. More recently, a role for the interaction between OX-A 
release in the arcuate nucleus and CB1R located in POMC neurons has been put forward 
in promoting hyperphagia [69]. Thus, the activation of OX1R by OX-A induces the 
synthesis of 2-AG, which binds to postsynaptic CB1R  in POMC cells leading to a 
decrease in POMC and α–melanocyte-stimulating hormone (α-MSH) synthesis in the 
paraventricular nucleus of the hypothalamus, and to hyperphagia (Figure 1). During 
obesity, characterized by leptin signaling deficiency, this system is hyperactivated and 
high levels of OX-A and 2-AG correlate with decreased α-MSH levels and increased body 
mass index [69].  
Interestingly, OX neurons have also been shown to protect the body from obesity by 
promoting energy expenditure [83]. Thus, the overexpression of OXs induces resistance 
to high fat diet-induced obesity and insulin insensitivity by promoting energy expenditure 
and reducing food consumption. This action of OX cells is partly mediated through OX2R 
and an increase in leptin sensitivity [84]. More recently, using in vivo calcium imaging it 
has been demonstrated that OX neurons are activated by hunger signals, but are rapidly 
inactivated by eating irrespective of the nature of the food, reducing food foraging and 
promoting storage of energy [85,86]. On the other hand, the complete selective 
inactivation of the OX system in the brain can promote overeating and increases body 
weight in free-feeding mice, a condition that is reversed by dieting [85]. These studies 
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indicate that the OX system is more involved in food seeking than in food consumption, 
and put forward the interesting notion that in pathological conditions where the activity 
of OX neurons is dysregulated, adjustments in food intake could play a normalizing role 
[85].  
The ECS also modulates body weight and fat mass, probably through peripheral 
lipogenesis [87]. In addition, chronic blockade of CB1R improves peripheral metabolic 
parameters. Notably, an interaction between the OX system and the ECS on feeding 
behavior and on the activity of glucose sensitive neurons in the arcuate nucleus has been 
recently suggested. Thus, the local administration of the CB1R antagonist AM251 into 
the arcuate nucleus modulates food intake induced by OX-A, and blunts its effects on 
glucose responsive neurons in this structure [88]. However, it is still not known whether 
the OX system and the ECS interact in periphery and in the brain to modulate energy 
balance.  
 
4. Involvement of endocannabinoids in the effects of orexins on nociception 
OX neurons project to several regions of the CNS involved in the regulation of pain, 
including the ventrolateral periaqueductal gray (vlPAG) and spinal dorsal horn, where 
OX receptors are densely distributed [30,32]. The descending antinociceptive pathway 
controls pain perception at the spinal level by the activation of PAG neurons leading to 
the excitation of cells in the rostroventral medulla, that send inhibitory projections to the 
dorsal horn of the spinal cord via the dorsolateral funiculus [89]. The antinociceptive 
effects of OXs have been widely demonstrated (see [41] for review), and one mechanism 
that has been proposed to explain this role is the interaction with the ECS at the level of 
the PAG. Hence, Ho et al. [90] have demonstrated that activation of OX1R by OX-A in 
PAG slices increases the synthesis of 2-AG via the phospholipase C-DAGLα route, and 
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inhibits GABAergic tone leading to an increase in PAG neuronal activity (Figure 1). This 
mechanism of action has also been postulated to contribute to stress-induced analgesia 
[91]. In addition, recent studies show that although both OX-A and an OX2R selective 
agonist injected in the vlPAG induce antinociception, only OX1R-mediated 
antinociception is blocked by the CB1R receptor antagonist AM 251 [42]. Moreover, the 
antinociceptive effect of intra-LH administration of carbachol is mediated through the 
activation of OX1R and OX2R in the vlPAG [92,93]. CB1R activation in this brain area 
also contributes to the modulation of carbachol-induced antinociception [92,93]. In 
addition, the OX system and the ECS interact at other brain areas involved in nociception, 
such as the LC since local administration of OX-A in this area induces analgesia through 
activation of OX1R and CB1R [94]. Finally, since eating disorders/obesity are often 
associated to altered pain perception [95], the relationship between the OX system and 
the ECS has been investigated in this case. Obese ob/ob mice exhibiting total leptin 
deficiency show hypoalgesic behavior associated with an increase in OX-A and 2-AG 
levels in the vlPAG, leading to the disinhibition of the vlPAG neurons and activation of 
the descending antinociceptive pathway [95]. Furthermore, these authors found that high 
fat diet-induced obese mice showing leptin signaling deficiency only in the arcuate 
nucleus, also present high levels of OX-A and 2-AG in the vlPAG, but analgesia is only 
unmasked following systemic leptin receptor antagonism. Therefore, they concluded that 
the activation of the descending antinociceptive pathway mediated by the interaction 
between the OX and ECS partly underlies the increased pain thresholds in conditions 





5. Involvement of endocannabinoids in the modulation of the brain reward system 
by orexins 
The OX system regulates the mesocorticolimbic dopaminergic pathway, which is the 
circuit responsible for the pleasure feelings associated with natural and drug rewards. 
Numerous studies have demonstrated a role for the OX system in the addictive properties 
of drugs of abuse [47,96], consistent with the existence of reciprocal connections between 
OX-rich nuclei and brain areas involved in reward processing [30], including the VTA 
and the nucleus accumbens. OXs seem to regulate reward seeking by modulating VTA 
dopaminergic transmission. In agreement, intra-VTA injection of OX-A increased 
extracellular dopamine levels in both the prefrontal cortex and the nucleus accumbens 
[97]. OXs influence VTA dopamine cell firing not only via direct depolarization [98], but 
also by interacting with glutamate and GABA transmission. Activation of GABAergic 
neurons in the VTA constitutes an inhibitory input on dopaminergic neurons, while 
increase of glutamate transmission is an excitatory influence on VTA dopaminergic 
activity. In brain slices, OXs were shown to increase dopaminergic activity in the VTA 
via long-term potentiation of glutamatergic transmission [99], and also by directly 
increasing the firing of GABAergic neurons [98]. Although activation of GABAergic 
cells is predicted to decrease VTA dopaminergic activity, OXs could facilitate a switch 
in the balance between excitatory and inhibitory synaptic inputs to VTA dopaminergic 
neurons in some conditions, such as the exposure to drugs of abuse. Indeed, the ability of 
OX to increase glutamate transmission in parallel with a decrease in GABA transmission 
in the VTA has been recently described in brain slices of animals treated with morphine 
by using electrophysiology [100]. On the other hand, it is well established that 
endocannabinoids and CB1R participate in the rewarding properties of natural rewards, 
and also in those induced by different drugs of abuse [45,101]. Acting as retrograde 
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messengers, endocannabinoids produce inhibition of neurotransmitter release in the VTA. 
The activation of CB1R located on axon terminals of GABAergic neurons in the VTA 
inhibits GABA transmission, thus removing this inhibitory input on dopaminergic 
neurons [102]. Glutamatergic transmission in the VTA, arising mainly from neurons of 
the prefrontal cortex, is similarly inhibited by CB1R activation [103]. The final effect of 
endocannabinoids on the modulation of VTA dopamine neurons, which depends on the 
balance between excitatory and inhibitory inputs, is predominantly excitatory [45]. 
A recent study has revealed an interesting interaction between OXs and endocannabinoids 
within the VTA in the regulation of cocaine relapse induced by stress [104]. In a sequence 
of elegant experiments, these authors demonstrated that acute restraint stress activates 
OX neurons in the LH, increases OX-A levels in the VTA, and reinstates extinguished 
conditioned place preference induced by cocaine. Notably, the activation of postsynaptic 
OX1R on VTA dopaminergic neurons by OXs leads to the production of 2-AG through 
the PLC and DAGL enzymatic cascade, which then retrogradely inhibits GABA release 
through CB1R, followed by the disinhibition of VTA dopaminergic neurons [104]. 
Moreover, stress-induced reinstatement of cocaine place preference was prevented by 
either systemic or intra-VTA injection of an OX1R or CB1R antagonist, and by a DAGL 
inhibitor [104]. This study provides a novel mechanism for stress-induced cocaine relapse 
based on this OX1R-PLC-DAGL-2-AG cascade in charge of the final disinhibition of 
VTA dopaminergic neurons (Figure 1). In agreement with this mechanism, a previous 
behavioral study showed that intra-VTA injection of CB1R receptor or OX1R antagonists 
produced comparable and non-additive reductions in the conditioned place preference 
induced by chemical stimulation of the LH with the cholinergic agonist carbachol [105]. 
This result suggests that CB1R and OX1R in the VTA regulate this behavioral response 
by a common mechanism, rather than activating two parallel pathways. In addition, an 
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interaction between CB1R  and both OX1R and OX2R in the nucleus accumbens has also 
been shown to be involved in the conditioned place preference induced by LH stimulation 
[106,107]. Recently, it has been described that OX2R and CB1R located in the VTA play 
a role in the rewarding properties of nicotine as revealed by using a conditioned place 
preference paradigm [108]. Future investigation at molecular, cellular and behavioral 
levels will be required to better understand the exact mechanisms and potential 
therapeutic implications of the interaction between these systems in the regulation of the 
reward circuit. The formation of CB1R-OX1R heteromers with specific signaling 
properties could be important for the interaction of these systems in the regulation of 
reward, as has been previously described for CB1R and dopamine D2 receptors [21].      
 
 
6. Involvement of orexins in the pharmacological effects of cannabinoids 
As described in the previous sections of this review, the contribution of the ECS in several 
physiological functions of OX has been clearly established.  However, so far few studies 
have evaluated whether the opposite is also occurring, that is, does the OX system 
participate in the pharmacological effects of cannabinoids? A relevant aspect of OX-
cannabinoid interplay is observed in the addictive properties of cannabinoids. Cannabis 
is the most frequently used illicit drug worldwide, and the number of people seeking 
treatment for cannabis use disorder has dramatically increased in the last decades [109]. 
Therefore, the identification of new therapeutic targets to improve treatment outcomes 
for cannabis dependence is imperative considering that currently there are no effective 
pharmacotherapeutic approaches for this disorder [110].  
The first evidence supporting the modulation of OXs on cannabis dependence was based 
on modifications in the expression of OX-A in peripheral blood cells in cannabis-
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dependent smokers when compared to nicotine-dependent smokers and non-smokers 
[111]. However, peripheral OX mRNA levels do not necessarily reflect the situation in 
the CNS; hence these differences are probably related to the peripheral actions of ∆9-
tetrahydrocannabinol (THC), and not to its central effects involved in the development of 
dependence. Nevertheless, subsequent behavioral studies have demonstrated that the OX 
system modulates cannabinoid reward. Thus, the intravenous self-administration of the 
synthetic cannabinoid WIN55,212-2 was reduced by both genetic deletion and 
pharmacological blockade of OX1R [112]. In contrast, OX2R were not involved in this 
response. Also, the increase in dopamine extracellular levels in the nucleus accumbens 
induced by THC was blocked in mice lacking the OX1R, suggesting that cannabinoids 
require orexinergic transmission to modulate the dopaminergic mesolimbic pathway. 
Moreover, contingent WIN55,212-2 self-administration, but not passive exposure to this 
cannabinoid, increased the activation of OX neurons in the LH [112], indicating that the 
recruitment of OX cells within this structure is mainly due to operant seeking for the 
reinforcing effects of this drug, and not to its pharmacological actions [112]. As a whole, 
these data show that OX1R antagonists could represent an interesting pharmacological 
tool for cannabis dependence in humans.  
In a more general sense, a recent study evaluated the involvement of the OX system in 
several acute pharmacological effects of THC. The hypothermia, supraspinal 
antinociception and anxiolytic-like effects induced by THC were modulated by OX 
through OX2R signaling [113]. In contrast, OXs were not shown to be involved in the 
hypolocomotion, spinal antinociception, amnesic- or anxiogenic-like effects produced by 
this cannabinoid. Interestingly, OX1R did not participate in any acute pharmacological 
effects of THC [113]. Therefore, the blockade of OX1R would specifically abolish the 
reinforcing properties of cannabinoids without affecting other pharmacological responses 
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of these compounds [112,113] (Figure 2). This is important since one of the major 
challenges in cannabinoid research consists in identifying possible mechanisms to 
dissociate the therapeutic action of cannabis from its detrimental consequences, among 
which cannabis addiction represents a pivotal concern.  
 
Concluding remarks 
Anatomical, biochemical and behavioral studies support the existence of bidirectional 
interactions between the ECS and the OX system. There is an increasing amount of data 
indicating that endocannabinoids exert a crucial modulation of the effects of OXs on food 
seeking and antinociception through the release of 2-AG in hypothalamic and brain stem 
areas. Moreover, new data is pointing towards a relevant role of OXs on stress-induced 
cocaine relapse also via a 2-AG-mediated mechanism in brain reward structures. This 
intriguing evidence emphasizes the prominent role of the endocannabinoid-mediated 
retrograde inhibition of GABAergic neurons in several major physiological brain 
functions: motivation for food and drug reward, as well as, a pain perception. The 
involvement of OX1R in the rewarding properties of cannabinoids, but not in other 
pharmacological effects, is of special interest since OX1R antagonists could be 
potentially useful to treat cannabis dependence without affecting other beneficial 
properties of these compounds. Although the mechanisms underlying this interaction are 
poorly understood, the existence of CB1R-OX1R heteromers with specific functional 
signaling properties could be the basis for some of these effects. The development of new 
tools to further probe this functional interaction may lead to novel therapeutic approaches 
to neurological disorders mediated by these receptors. This field, where OXs meet 
cannabinoids will certainly expand with time as research develops on their molecular and 
behavioral interactions, providing deeper insight into its relevance in physiological and 
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pathological conditions, and a better understanding of their potential therapeutic 
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Figure 1. Orexins repress neuronal activity through endocannabinoid signaling. 
Upon orexin release, activation of postsynaptic OX1R leads to biosynthesis of the 
endocannabinoid 2-arachidonoylglycerol (2-AG) through a Gq-protein-phospholipase C- 
diacylglycerol lipase (PLC-DAGL) cascade. 2-AG diffuses to the extracellular space and 
activates CB1R present in surrounding cells, producing hyperpolarization of the neuronal 
membrane and inhibiting subsequent neurotransmitter release at the axon terminal. This 
mechanism has functional consequences at diverse orexinergic target sites: 1. Within the 
ventral tegmental area (VTA), OX1R-induced 2-AG release leads to inhibition of 
GABAergic interneurons and subsequent disinhibition of dopaminergic neurons, 
contributing to cocaine relapse; 2. In the arcuate nucleus (ARC), POMC neurons are 
retrogradely inhibited by their own OX1R-induced 2-AG generation, this leads to 
diminished satiety signaling, producing hyperphagia and contributing to obesity; 3. 
Within the periaqueductal gray (PAG) GABAergic interneurons are also inhibited by 2-
AG release, resulting in disinhibition of non-determined antinociceptive pathways. PIP2, 
phosphatidylinositol 4,5-bisphosphate; DAG, diacylglycerol; NT, neurotransmitter; OX, 
orexin neurons; LH, lateral hypothalamus. 
Figure 2. Orexinergic modulation of cannabinoid-induced behavioral effects. 
Exogenous cannabinoids, such as THC or WIN55,212-2, produce a series of behavioral 
responses, presumably through CB1R. Some of these responses are independent of orexin 
transmission, including hypolocomotion, anxiogenic-like and amnesic-like effects. 
However, antinociception, hypothermia and anxiolytic-like responses are modulated by 
OX2R signaling. Besides, OX1R stimulation contributes to cannabinoid-induced 
reinforcement. This means that selective OX1R antagonists could be employed as a 
therapeutic tool to prevent the potential abuse liability associated to cannabinoid-based 
therapies while preserving their beneficial effects.  
